AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 278: R1057-R1063, 2000;
0363-6119/00 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (35)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiao, Q.
Right arrow Articles by Brubaker, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, Q.
Right arrow Articles by Brubaker, P. L.
Vol. 278, Issue 4, R1057-R1063, April 2000

Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease

Qiang Xiao1,*, Robin P. Boushey2,*, Maria Cino3, Daniel J. Drucker3,4, and Patricia L. Brubaker1,3

Departments of 1 Physiology, 3 Medicine, and 2 Surgery, Mount Sinai Hospital and the Toronto General Hospital, Toronto M5G 2C4; and the 4 Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada M5S 1A8

Glucagon-like peptide-2 (GLP-2) is a recently characterized intestine-derived peptide that exerts trophic activity in the small and large intestine. Whether circulating levels of GLP-2 are perturbed in the setting of human inflammatory bowel disease (IBD) remains unknown. The circulating levels of bioactive GLP-2-(1---33) compared with its degradation product GLP-2-(3---33) were assessed using a combination of RIA and HPLC in normal and immunocompromised control human subjects and patients hospitalized for IBD. The activity of the enzyme dipeptidyl peptidase IV (DP IV), a key determinant of GLP-2-(1---33) degradation was also assessed in the plasma of normal controls and subjects with IBD. The circulating levels of bioactive GLP-2-(1---33) were increased in patients with either ulcerative colitis (UC) or Crohn's Disease (CD; to 229 ± 65 and 317 ± 89%, P < 0.05, of normal, respectively). Furthermore, the proportion of total immunoreactivity represented by intact GLP-2-(1---33), compared with GLP-2-(3---33), was increased from 43 ± 3% in normal healthy controls to 61 ± 6% (P < 0.01) and 59 ± 2% (P < 0.01) in patients with UC and CD, respectively. The relative activity of plasma DP IV was significantly reduced in subjects with IBD compared with normal subjects (1.4 ± 0.3 vs. 5.0 ± 1.1 mU/ml, respectively; P < 0.05). These results suggest that patients with active IBD may undergo an adaptive response to intestinal injury by increasing the circulating levels of bioactive GLP-2-(1---33), facilitating enhanced repair of the intestinal mucosal epithelium in vivo.

Crohn's disease; ulcerative colitis; short bowel syndrome; intestine

* Q. Xiao and R. P. Boushey were equal contributors to this study.




This article has been cited by other articles:


Home page
 GutHome page
J. R O'Hara, A. E Lomax, G. M Mawe, and K. A Sharkey
Ileitis alters neuronal and enteroendocrine signalling in guinea pig distal colon
Gut, February 1, 2007; 56(2): 186 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
A. E. Lomax, J. R. O'Hara, N. P. Hyland, G. M. Mawe, and K. A. Sharkey
Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis
Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G482 - G491.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Stephens, B. Stoll, J. Cottrell, X. Chang, M. Helmrath, and D. G. Burrin
Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R283 - R289.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
K. E. Mayo, L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, and D. J. Drucker
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Pharmacol. Rev., March 1, 2003; 55(1): 167 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Ni, Y. Anini, X. Fang, G. Mills, P. L Brubaker, and T. Jin
Transcriptional Activation of the Proglucagon Gene by Lithium and beta -Catenin in Intestinal Endocrine L Cells
J. Biol. Chem., January 3, 2003; 278(2): 1380 - 1387.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D J Drucker
Gut adaptation and the glucagon-like peptides
Gut, March 1, 2002; 50(3): 428 - 435.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online